Stroke is one of the major leading causes of death and disability worldwide, and post-stroke cognitive impairment is a major contributor to this disability.
A C C E P T E D M A N U S C R I P T
. AST-IV, a key bioactive component of Radix Astragali, has attracted increasing attention in recent years due to its potential therapeutic benefits for stroke-related cognitive impairment (Kim et al., 2015; Li et al., 2017) . Here, we investigated the protective effects of AST-IV in cortical neurons subjected to oxygen and glucose deprivation (OGD; in vitro model of ischemic injury) and explored the possible mechanisms underlying the action of AST-IV.
Serine/threonine protein kinases are highly expressed in the central nervous system and are severely altered in response to ischemic insults (Domańska-Janik, 1996) .
Reduced phosphorylation of protein kinase A (PKA) was shown to play a critical role in the progression of post-ischemic brain injury . Cyclic AMP response element-binding protein (CREB), a transcription factor activated by PKA, has been shown to regulate transcription in neurogenesis and was also implicated in cerebral ischemia (Schölzke and Schwaninger, 2007; Kitagawa, 2007) . CREB regulates a variety of intracellular signaling events, including neuronal growth, proliferation, synaptic efficacy, and long-lasting changes in synaptic plasticity, which affects the processes of memory and cognition (Saura and Cardinaux, 2017; Paramanik and Thakur, 2013; Yu et al., 2017) . It has been found to exist and act both in the nucleus and the mitochondrial matrix (Ryu et al., 2005) . Aberrant energy metabolism following cerebral ischemia induces mitochondrial impairments leading to reduced respiration, excessive production of reactive oxygen species (ROS), and depletion of adenosine triphosphate (ATP) (Perez-Pinzon, 2004; Fiskum et al., 1999) .
Therefore, maintaining mitochondrial health is critical in promoting ischemic tolerance by enhancing neuronal viability following ischemic injury (Perez-Pinzon et al., 2012) .
Pregnant rats were euthanized using carbon dioxide at embryonic day 18. The fetuses were collected in ice-cold HBSS supplemented with 0.5% penicillin/streptomycin (P/S). They were decapitated and the whole brain was transferred into fresh, cold Dulbecco's modified Eagle medium (DMEM)/F12 with 0.5% P/S. The isolated cerebral cortices were minced and incubated at 37°C for 20 min in a solution of 0.125% trypsin. The tissue was washed in DMEM/F12 containing 10% fetal bovine serum and then passed through a 200-mesh filter screen. Following 15 min of centrifugation at 800 g and 4°C, the pellet was resuspended in 4 mL Primary Neuron Basal Medium supplemented with 2% B27, 0.5% P/S, and Glutamax. Next, the cells were plated at a density of 1 × 10 6 cells/mL onto lysine-coated 96-or 6-well plates.
Specifically, there were 1 × 10 5 cells/well in the 96-well plates (100 μL/well) and 1 × 10 6 cells/well in the 6-well plates (1 mL/well). Half of the medium was changed every three days.
Assessment of Cell Purity
Immunofluorescent staining of cultured cells was performed using antibody against MAP2 on 5 th day after neuron isolation. Cells were rinsed with PBS, fixed in 4% paraformaldehyde in 0.01 mol/L PBS (pH 7.2) at room temperature for 25 min and 
OGD model and AST-IV treatment
After 5-6 days in culture, the OGD/reoxygenation protocol was commenced; the culture medium was changed to low-glucose HBSS and the neurons were incubated in a hypoxic incubator with 1% O 2 , 5% CO 2 , and saturated humidity at 37°C for 3 h.
Following OGD, the neurons were reoxygenated in 95% air-5% CO 2 and
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A C C E P T E D M A N U S C R I P T glucose-containing medium for 24 h prior to any further testing [Yanqiu, et al., 2017] .
The treatment paradigm and timeline is illustrated in Fig. 1 . For control cells (naive)
that did not undergo OGD, the culture medium was replaced with regular glucose-containing culture medium and the cells were grown under normal oxygen conditions.
AST-IV was first diluted in low amounts of dimethyl sulfoxide (DMSO) ensuring that the final proportion of DMSO did not exceed 1/1000. Then low volumes of HBSS were repeatedly added and the AST-IV was slowly dissolved with warming and sonication. The final concentration of AST-IV was brought to 25, 12.5, and 6.25 μmol/L, which our preliminary dose-response tests found to be most efficient. The vehicle for AST-IV was 1/1000 DMSO in HBSS. AST-IV solution or vehicle was added to the neuronal cultures at the same time as the start of OGD and remained in the culture medium throughout the OGD and reoxygenation (Fig. 1) .
Cell viability and cytotoxicity assays
Following the OGD/reoxygenation of cortical neurons, we measured cell viability and cytotoxicity with and without AST-IV treatment. The viability of the primary neurons was evaluated by the CCK-8 assay. Briefly, 10 µL of CCK-8 was added to each well, and cells were further incubated for 1 h at 37°C. Absorbance was then measured at 450 nm using a microplate reader (BioTek STNERGYT TM 4, USA). Cytotoxicity was determined by a detection assay that measured the release of lactate dehydrogenase (LDH) from cells to reflect levels of cytotoxicity. A 50-μL aliquot of medium from the samples was transferred to another new 96-well plate. Then equivalent dose of manufacturer-provided test reagent was added to each well for measurement of the release of LDH from the cells. Optical density was determined at 490 nm using a microplate reader.
Measurement of mitochondrial membrane potential (ΔΨm) in neurons
ΔΨm was estimated in the mitochondria of neurons using the JC-1 dye according to 
ROS quantification in primary neurons
To measure ROS levels, primary neurons were exposed to OGD by incubation in low-glucose HBSS under hypoxic conditions (1% O 2 , 5% CO 2 ) for 3 h. 
ATP-release assay in neuronal mitochondria
ATP release was detected using the ATPlite Luminescence ATP Detection Assay System (PerkinElmer EnSpire TM , USA) according to the manufacturer's protocol.
Briefly, following OGD/reoxygenation and AST-IV treatment, neurons were washed with PBS. Then, they were incubated in 100 μL culture medium, to which 50 μL lysis buffer (from the ATPlite kit) was added for 5-10 min until neurons were completely fragmented. Finally, 50 μL substrate (from the ATPlite kit) was added for a 5 min incubation and the ATP content was measured on a multifunction microplate reader (Jarboe et al., 2012) .
Western blotting
The immunoblotting procedure was performed as previously described (Stephen et al., 2015) . We used primary antibodies against cleaved caspase-3, caspase-3, p-PKA,
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PKA, p-CREB, CREB, and β-actin. HRP-conjugated goat anti-rabbit IgG was used as a secondary antibody. Briefly, Denatured proteins from neurons were separated by molecular weight using SDS-PAGE. The proteins in the gels were transferred to polyvinylidene fluoride membrane using a Trans-Blot Cell (Bio-Rad, USA). The membrane was blocked from nonspecific recognition of antibody with 5% skim milk or bovine serum albumin (for phosphorylated protein) dissolved in TBST. The proteins were detected using the indicated antibodies by means of an enhanced chemiluminescence system. Specially, the blot was stripped for phosphorylated proteins and blotted again for total proteins.
Statistical analysis
All data were analyzed using SPSS 22.0 and presented as the means ± standard deviation (SD). Graphs were generated in GraphPad Prism 5. One-way analysis of variance (ANOVA) was performed to assess the statistical significance among multiple groups. Post-hoc pairwise comparisons were made by Tukey's HSD if homogeneity of variance was met or Games-Howell if the variance was unequal.
Comparisons with P < 0.05 were considered to show a statistically significant difference.
RESULTS
Verification of cortical neuronal culture and AST-IV doses
In order to ensure that the proportion of astrocytes was relatively small in the culture system, we measured the immunofluorescence of the neuronal marker MAP2 and used Hoechst 33342 to stain all cell nuclei. As shown by the colocalization in Fig. 2A , we found that the majority of the cells in our culture preparation were neurons. We Effects of AST-IV on primary cortical neuronal activity, morphology, and apoptosis induced by OGD.
OGD in neurons has been used as a rapid and sensitive in vitro model of ischemic stroke by many studies investigating potential neuroprotective agents (Wieloch et al., 2003; Nistico et al., 2009) . To evaluate the protective effects of AST-IV against ischemic injury, we treated primary neurons with AST-IV and subjected them to OGD for 3 h. As shown in shrunken somas, which were partially reversed by AST-IV treatment (Fig. 3C ).
Furthermore, we performed immunoblots to examine the effects of AST-IV on OGD-induced neuronal apoptosis. Cleaved caspase-3 expression was increased in the OGD group but was reduced significantly in cells that received AST-IV treatment (F (4, 10) = 20.5, P < 0.0001; post-hoc Turkey, P = 0.03 for OGD vs. AST-IV 25 μmol/L, Fig. 3D ). The change in Δψm is an indicator of the early stages of neuronal apoptosis and is described in the next section. Collectively, these results confirmed that AST-IV treatment improved neuronal viability and prevented OGD-induced apoptosis in primary neurons.
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A C C E P T E D M A N U S C R I P T Effects of AST-IV on OGD-induced mitochondrial dysfunction
To determine the potential mechanisms underlying the protective effects of AST-IV against OGD, we tested whether AST-IV could preserve mitochondria. As shown in AST-IV 25 μmol/L and P = 0.047 for OGD vs. AST-IV 12.5 μmol/L). Therefore, these data collectively demonstrated that the protective effects of AST-IV against OGD were elicited by modulating ROS and ATP production to preserve healthy mitochondrial function.
Effects of AST-IV on the PKA/CREB signaling pathway
It has been reported that PKA/CREB was involved in preserving mitochondrial function and regulating ROS and ATP levels in mitochondria (Xie et al., 2017; Signorile et al., 2014) . Furthermore, the expression of PKA/CREB was down-regulated during cerebral ischemia (Niu et al., 2014) . Since this study (see the 
DISCUSSION
Ischemic stroke leads to neuronal dysfunction and cognitive impairment (Mijajlović et al., 2017) . The current clinical treatments for ischemic stroke are mostly limited to thrombolytics, such as recombinant tissue plasminogen activator, that have a very restricted window for success following the injury (Zerna et al., 2016) . Mitochondrial impairment was found to be one of the key pathological events that occur in the early stages of ischemic injury (Kahl et al., 2018; Aggarwal, 2010) . Previous studies have elucidated the critical role of mitochondria in the cell; this organelle fulfills numerous cellular functions including ATP production, buffering of calcium ions (Ca 2+ ), ROS production and sequestration, apoptosis, and neurotransmitter synthesis and inactivation (Brini et al., 2014; Tait and Green, 2013; Zorov et al., 2014; Rowley et al., 2012 ). However, mitochondria were shown to be vulnerable to ischemic injury due to the accompanying deficiency in oxygen and glucose (Novgorodov et al., 2016) , and mitochondria-related potential therapies for stroke are gaining traction in the field.
Decreased mitochondrial membrane potential is an indication that the mitochondrial membrane has been permeabilized, which is an early sign of OGD-induced neuronal apoptosis (Parra et al., 2008; . Accordingly, restoration of
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A C C E P T E D M A N U S C R I P T mitochondrial membrane potential is often used as a readout for the efficacy of potential therapies.
Accumulating evidence suggests a close relationship between excessive ROS production and neuronal death in various neurological disorders, including amyotrophic lateral sclerosis, Alzheimer's disease (AD), Parkinson's disease (PD), ischemic stroke, and traumatic brain injury (Cadenas and Davies, 2000; Valko et al., 2007) . Mitochondrial dysfunction has been shown to cause the generation of the highly reactive species peroxynitrite (ONOO − ), which led to excessive ROS production and further inhibited the function of mitochondrial complexes (Dugan et al., 2009; Aggarwal et al., 2010) . Moreover, production of ROS in this way can damage virtually every biomolecule found in cells, promote opening of mitochondrial PTPs, and activate inflammatory and thrombogenic cascades to exacerbate cell injury (Theodore et al., 2016) . Many natural agents, such as AST-IV and ginkgo biloba extract, show promising antioxidant activity Zhou et al., 2017) .
Furthermore, mitochondrial superoxide dismutase, an enzyme that neutralizes ROS, as well as antioxidants such as azulenyl nitrones, have shown promising results in preclinical studies of ischemic stroke (Tsubokawa et al., 2007; Ginsberg et al., 2003) .
Some reports have considered that antioxidants may modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons Hoon et al., 2005) . Methylene blue, which enhances mitochondrial ATP production and propogates the electron transport chain, has been shown to reduce infarct size and improve cerebral blood flow (Lora et al., 2013) .
AST-IV is one of the most important bioactive compounds of the herb Radix
Astragali that is widely used in Chinese traditional medicine for the treatment of cerebrovascular diseases (Hu et al., 2012; Ren et al., 2013) . The pharmacological effects of AST-IV include cardiac protective function (Chen et al., 2011 ), anti-asthma (Du et al., 2008 , and anti-stroke properties (Li et al., 2013) . In this study, we demonstrated that AST-IV improved mitochondrial activity in cortical neurons subjected to OGD; it regulated the generation of ROS and ATP, and inhibited OGD-induced neuronal apoptosis. These findings revealed a mitochondria-mediated
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A C C E P T E D M A N U S C R I P T mechanism underlying the neuroprotective effects of AST-IV and provided further evidence to support the use of Radix Astragali in the treatment of ischemic stroke.
The activity of mitochondria has been shown to be regulated by PKA/CREB signaling (Ryu et al., 2005; Lee et al., 2005) . Numerous studies have demonstrated the essential role of CREB in memory and cognitive function (Saura and Cardinaux, 2017; Tully, 1997) . CREB was reported to regulate a variety of intracellular signaling events, including cellular growth, proliferation, synaptic efficacy, and long-lasting changes in synaptic plasticity (Dugan et al., 2009; Babikian et al., 1990; Meyer et al., 1988) .
PKA is an upstream component of the signaling pathway with CREB that can modulate CREB activity by phosphorylating it on Serine 133 (Naqvi, et al., 2014) .
CREB can not only trigger gene expression in the nucleus but was also reported to exist in the mitochondrial matrix of neurons to ensure efficient signal propagation between the neuronal membrane and mitochondria (Ryu et al., 2005; Lee et al., 2005) .
The PKA/CREB signaling pathway was shown to modulate ROS and ATP generation to preserve mitochondria (Ryu et al., 2005) .
The links between AST-IV, ischemic stroke, mitochondrial dysfunction, and PKA/CREB signaling prompted our hypothesis that AST-IV protects OGD-exposed neurons from injury and death by preserving mitochondrial function via the regulation of PKA/CREB pathway. The results demonstrated that the protective effects of AST-IV were partially blocked by PKA inhibitor H-89, indicating that AST-IV protected mitochondria and enhanced neuronal viability by activating the PKA/CREB pathway. Previous studies have shown that AST-IV attenuated cognitive impairment caused by stroke (Kim et al., 2015; Li et al., 2017) ; however, the associated mechanism was never elucidated. In this study, we found that the OGD-induced decrease in CREB was reversed by AST-IV treatment. Our observations of AST-IV's regulation of CREB and its requirement of PKA elucidated one of the mechanisms underlying its protection against OGD-induced ischemic injury.
Based on the results of this study, we believe that PKA/CREB was the primary pathway targeted by AST-IV; however we also observed that H-89 exposure did not block the positive effect of AST-IV on ROS production, which indicated that PKA
A C C E P T E D M A N U S C R I P T
was not the only kinase by which AST-IV acted. In fact, it has been reported that regulatory kinases of CREB also included MAPK, AKT, and CaMKII (C. Unsöld et al., 1998) . In addition, AST-IV treatment of neurons subjected to H 2 O 2 showed an increase in phosphorylated p38 MAPK . Therefore,
PKA-independent signaling pathways should also be investigated in the future to comprehensively understand the mechanisms underlying AST-IV's beneficial effects in ischemic injury.
The activity of PKA is dependent on the cellular level of cAMP (Gorshkov et al., 2017) . We speculate that AST-IV triggers neuroprotection via the PKA/CREB pathway by binding to G-protein coupled receptors that regulate cAMP activity.
Several reports in the literature support this idea: (1) The specific receptors that interact with AST-IV are associated with protease-activated receptor-2 (PAR2) , G protein-coupled receptor kinase-2 (GRK2)-CXCR2 (Huang et al., 2016) , CXCR4 (Xie et al., 2013) , and CC chemokine receptor 3 (CCR3) (Gu et al., 2012) , all of which are G-protein coupled receptors. (2) It was also reported that the PKA/CREB pathway lay downstream of a G-protein coupled receptor (Bauman et al., 2006) . Therefore, we believe that following an ischemic injury, AST-IV may interact with the G-protein coupled receptors, promote the membrane-associated adenylyl cyclase to generate cAMP, activate the PKA/CREB pathway, regulate the generation of ROS and ATP, and finally inhibit neuronal apoptosis and increase neuronal survival.
While we successfully revealed a mechanism of AST-IV with an in vitro model of ischemic injury, we did not use animal models to verify this PKA/CREB/ mitochondria-mediated protective pathway in ischemia. However, other animal studies of AST-IV in ischemia indirectly corroborated our findings. One study in rats subjected to ischemia/reoxygenation injury revealed that AST-IV protected brain tissue by inhibiting peripheral benzodiazepine receptors (PBRs) (Cao et al., 2015) , which are found in the mitochondrial outer membrane and are involved in oxidative processes and mitochondrial function (Casellas et al., 2002) . Another study reported
A C C E P T E D M
A N U S C R I P T that AST-IV accomplished its neuroprotective effects in ischemic mice by blocking the activation of the NLRP3 inflammasome (Yu and Lee, 2016) , a downstream consequence of mitochondrial dysfunction and excess ROS production (Yu and Lee, 2016) .
In summary, we have shown that AST-IV protected against OGD-induced apoptosis in primary neurons by regulating the PKA/CREB pathway and preserving mitochondrial function. As the OGD-induced down-regulation of CREB plays a critical role in cognitive impairment associated with ischemic injury, our study strongly suggests that AST-IV could be effective in treating cognitive impairments associated with ischemic stroke. Our findings provide a better understanding of the molecular mechanisms underlying the neuroprotective effects of AST-IV and could offer new insight into potential therapeutic targets to treat ischemic injury. AST-IV treatment paradigm. Cortical tissue was extracted from rat fetuses at embryonic day (E) 18 and neurons were allowed to mature in culture for 5-6 days.
A C C E P T E D
AST-IV was administered at the start of the OGD protocol (3 h). All experiments were conducted 24 h after the cells were returned to glucose and AST-IV-containing media and normal oxygen conditions (reoxygenation). by total caspase-3 and β-actin (right). n = 3. *P < 0.05, **P < 0.01, and ***P < 0.001
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T compared with the OGD group. Cas-3, caspase-3; CCK-8, cell counting kit 8; LDH, lactate dehydrogenase. The quantified levels of ROS are expressed as the means ± SD. n = 5. (C) Neuronal ATP production was measured by an ATPlite assay and the values are expressed as the fold difference from the ATP level of the OGD group. n = 5. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the OGD group. The data were analyzed by one-way ANOVA followed by a post-hoc. *P < 0.05 and **P < 0.01 compared with the OGD group. # P < 0.05 and ## P < 0.01 compared with the OGD + AST-IV group. The data shown are representative of at least three separate assays.  AST-IV prevented the cytotoxicity and cell apoptosis induced by OGD in primary cortical neurons.
 AST-IV reversed OGD-induced mitochondrial dysfunction (low mitochondrial potential, high ROS production, and low ATP).
 AST-IV increased PKA activation, which in turn increased CREB phosphorylation in primary neurons subjected to OGD.  The PKA inhibitor, H-89, blocked the effects of AST-IV in OGD-exposed cortical neurons. 
